# Neutrophil Extracellular Traps in Cancer Metastasis: From Mechanistic Understanding to Targeted Therapy

**Authors:** Xiaorui Tian, Jintong Na, Xinyi Tan, Fengqiu Dang, Rui Zhu, Liping Zhong, Yongxiang Zhao

PMC · DOI: 10.3390/curroncol33030156 · 2026-03-09

## TL;DR

This review explains how neutrophil extracellular traps (NETs) contribute to cancer metastasis and explores potential therapies targeting them.

## Contribution

The paper provides a comprehensive overview of NETs' roles in metastasis and highlights novel therapeutic strategies.

## Key findings

- NETs contribute to multiple stages of metastasis, including tumor cell survival and colonization.
- Psychological stress and tumor-secreted cytokines are key drivers of NET formation.
- Targeting NETs may offer new treatment options for metastatic cancer.

## Abstract

Metastasis is the leading cause of cancer-related deaths, highlighting the need to understand its mechanisms. Neutrophil extracellular traps (NETs) play a crucial role in tumor progression and metastasis. This review discusses the primary stimuli and signaling pathways driving NET formation, including factors like psychological stress, tumor-secreted cytokines, and treatment responses. NETs contribute to various stages of metastasis, including angiogenesis, tumor cell intravasation and extravasation, circulating tumor cell survival, metastatic colonization, and dormant tumor cell reactivation. They also help establish an immunosuppressive microenvironment. Finally, emerging strategies targeting NETs are explored for their potential in metastatic cancer treatment.

Metastasis is the leading cause of cancer-related death, underscoring the need to elucidate the key mechanisms behind this process. Neutrophil extracellular traps (NETs) have emerged as critical regulators of tumor progression and metastasis. This review summarizes the primary stimuli and signaling pathways that govern NET formation and outlines the mechanistic roles of NET components in tumor growth and metastatic spread. We focus on environmental and tumor microenvironment-derived factors, including psychological stress, tumor-secreted cytokines, and treatment-related responses, that drive NET formation. The involvement of NETs in multiple stages of the metastatic cascade is discussed, including angiogenesis, tumor cell intravasation and extravasation, circulating tumor cell survival, metastatic colonization, and the reactivation of dormant tumor cells. Additionally, we examine how NETs contribute to the establishment of an immunosuppressive microenvironment. Finally, emerging therapeutic strategies targeting NETs are briefly reviewed, highlighting their potential relevance in metastatic cancer treatment.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Pink1 (PTEN induced putative kinase 1) [NCBI Gene 68943] {aka 1190006F07Rik, BRPK, mFLJ00387}, Pdcd1 (programmed cell death 1) [NCBI Gene 18566] {aka Ly101, PD-1, Pdc1}, Dnase1 (deoxyribonuclease I) [NCBI Gene 13419] {aka DNaseI, Dnl1}, Ccl5 (C-C motif chemokine ligand 5) [NCBI Gene 20304] {aka MuRantes, RANTES, SISd, Scya5, TCP228}, Tsp1 (tumor suppressor region 1) [NCBI Gene 108314] {aka MTS}, Trav6-3 (T cell receptor alpha variable 6-3) [NCBI Gene 328483] {aka Gm13948, Gm193, Gm4, TCR}, Agt (angiotensinogen) [NCBI Gene 11606] {aka AngI, AngII, Aogen, Serpina8}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Gsk3a (glycogen synthase kinase 3 alpha) [NCBI Gene 606496] {aka 2700086H06Rik}, Padi2 (peptidyl arginine deiminase, type II) [NCBI Gene 18600] {aka Pdi, Pdi2, mKIAA0994}, Mmp2 (matrix metallopeptidase 2) [NCBI Gene 17390] {aka Clg4a, GelA, MMP-2}, Tgm2 (transglutaminase 2, C polypeptide) [NCBI Gene 21817] {aka G[a]h, TG2, TGase2, tTG, tTGas}, Hc (hemolytic complement) [NCBI Gene 15139] {aka C5, C5a, He, Hfib2}, Serpina1c (serine (or cysteine) peptidase inhibitor, clade A, member 1C) [NCBI Gene 20702] {aka Pi3, Pi6, Skalp, Spi1-3, Spi1-6, Wap3}, Twist1 (twist basic helix-loop-helix transcription factor 1) [NCBI Gene 22160] {aka M-Twist, Pde, Ska10, Ska<m10Jus>, Twist, bHLHa38}, Prlr (prolactin receptor) [NCBI Gene 19116] {aka Pr-1, Pr-3, Prlr-rs1}, Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Lmna (lamin A) [NCBI Gene 16905] {aka Dhe}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, Parva (parvin, alpha) [NCBI Gene 57342] {aka 2010012A22Rik, 5430400F08Rik, Actp, CH-ILKBP, Parvin}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Slc6a4 (solute carrier family 6 (neurotransmitter transporter, serotonin), member 4) [NCBI Gene 15567] {aka 5-HTT, Htt, Sert}, Ppia (peptidylprolyl isomerase A) [NCBI Gene 268373] {aka Cphn, CyP-18, CypA, SP18}, Dmbt1 (deleted in malignant brain tumors 1) [NCBI Gene 12945] {aka CRP, CRP-[a], CRP-[b], Crpd, DBMT1, gp300}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, CXCR2 (C-X-C motif chemokine receptor 2) [NCBI Gene 3579] {aka CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB}, Snai1 (snail family zinc finger 1) [NCBI Gene 20613] {aka Sna, Sna1, Snail, Snail1}, Jak2 (Janus kinase 2) [NCBI Gene 16452] {aka Fd17}, Sell (selectin, lymphocyte) [NCBI Gene 20343] {aka CD62L, L-selectin, LAM-1, LECAM-1, LECAM1, Lnhr}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, CXCR1 (C-X-C motif chemokine receptor 1) [NCBI Gene 3577] {aka C-C, C-C-CKR-1, CD128, CD181, CDw128a, CKR-1}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, Rac1 (Rac family small GTPase 1) [NCBI Gene 19353] {aka D5Ertd559e}, Cxcl5 (C-X-C motif chemokine ligand 5) [NCBI Gene 20311] {aka AMCF-II, Cxcl6, ENA-78, GCP-2, LIX, Scyb5}, Ctsc (cathepsin C) [NCBI Gene 13032] {aka CatC, DPP1, DPPI}, Dapk2 (death-associated protein kinase 2) [NCBI Gene 13143], Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Ccnd3 (cyclin D3) [NCBI Gene 12445] {aka 9230106B05Rik}, MPO (myeloperoxidase) [NCBI Gene 4353], Ctsg (cathepsin G) [NCBI Gene 13035] {aka CatG, VSP}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, Cd44 (CD44 antigen) [NCBI Gene 12505] {aka HERMES, Ly-24, Pgp-1}, Ccdc25 (coiled-coil domain containing 25) [NCBI Gene 67179] {aka 2610528H13Rik, NSrp70}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 20315] {aka Pbsf, Scyb12, Sdf1, Tlsf, Tpar1}, Cxcl13 (C-X-C motif chemokine ligand 13) [NCBI Gene 55985] {aka 4631412M08Rik, ANGIE2, Angie, BCA-1, BLC, BLR1L}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Vim (vimentin) [NCBI Gene 22352], Il33 (interleukin 33) [NCBI Gene 77125] {aka 9230117N10Rik, Il-33, Il1f11, NF-HEV}, Tlr9 (toll-like receptor 9) [NCBI Gene 81897], Mif (macrophage migration inhibitory factor (glycosylation-inhibiting factor)) [NCBI Gene 17319] {aka DER6, GIF, Glif}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Il1 (interleukin 1 complex) [NCBI Gene 111343] {aka Il-1}, PADI4 (peptidyl arginine deiminase 4) [NCBI Gene 23569] {aka PAD, PAD4, PADI5, PDI4, PDI5}
- **Diseases:** Inflammation (MESH:D007249), thrombosis (MESH:D013927), TANs (MESH:D000072716), pancreatic cancer (MESH:D010190), breast-to (MESH:D061325), liver fibrosis (MESH:D008103), colon cancer (MESH:D015179), lung (MESH:D008171), ovarian cancer (MESH:D010051), mitochondrial damage (MESH:D028361), atherosclerosis (MESH:D050197), colon (MESH:D003108), HCC (MESH:D006528), lymphoma (MESH:D008223), bladder cancer (MESH:D001749), tumorigenic (MESH:D002471), necrotic (MESH:D009336), gastric cancer (MESH:D013274), breast and prostate cancer (MESH:D001943), cytotoxic (MESH:D064420), lymphatic metastasis (MESH:D008207), leukemia (MESH:D007938), ventricular fibrillation (MESH:D014693), Cancer (MESH:D009369), vascular injury (MESH:D057772), acute liver injury (MESH:D017114), tumorigenesis (MESH:D063646), chronic hepatitis (MESH:D006521), peritoneal metastasis (MESH:D010538), death (MESH:D003643), Metastasis (MESH:D009362), prostate cancer (MESH:D011471), hypoxia (MESH:D000860), disease (MESH:D004194), glioma (MESH:D005910), injury to (MESH:D014947), melanoma (MESH:D008545), Lewis lung carcinoma (MESH:D018827), ascites (MESH:D001201), CCA (MESH:D018281)
- **Chemicals:** heme (MESH:D006418), doxorubicin (MESH:D004317), Au (MESH:D006046), cisplatin (MESH:D002945), PMA (MESH:D013755), lipid (MESH:D008055), EGCG (MESH:C045651), fluoxetine (MESH:D005473), reparixin (MESH:C490707), cryptotanshinone (MESH:C037886), nilotinib (MESH:C498826), exenatide (MESH:D000077270), ATP (MESH:D000255), LPS (MESH:D008070), Cl- (MESH:D002713), FAD (MESH:D005182), PR (MESH:D011221), TC (MESH:D013667), sulfoxide (MESH:C005746), mPDA (MESH:C056728), Cl-amidine (MESH:C558727), palmitic-acid (MESH:D019308), chloride (MESH:D002712), H2O2 (MESH:D006861), oxygen (MESH:D010100), mitoxantrone (MESH:D008942), DPI (MESH:C007517), paclitaxel (MESH:D017239), ATN-161 (MESH:C404392), phorbol esters (MESH:D010703), HOCl (MESH:D006997), DNaseI@Au (-), BMS-986253 (MESH:C000709704), ginsenoside Rg1 (MESH:C035054), CPT (MESH:C000708228), Icariin (MESH:C056599)
- **Species:** Adeno-associated virus (species) [taxon 272636], Panax ginseng (Asiatic ginseng, species) [taxon 4054], Escherichia coli (E. coli, species) [taxon 562], Homo sapiens (human, species) [taxon 9606], Salvia miltiorrhiza (Chinese salvia, species) [taxon 226208], Mus musculus (house mouse, species) [taxon 10090], Staphylococcus aureus (species) [taxon 1280]
- **Cell lines:** MMTV — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_KS75), LLC — Mus musculus (Mouse), Malignant tumors of the mouse pulmonary system, Cancer cell line (CVCL_5653), CT26 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_7254), MC38 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_B288), MB49 — Mus musculus (Mouse), Mouse bladder transitional cell carcinoma, Cancer cell line (CVCL_7076), C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), SW480 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0546)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025878/full.md

---
Source: https://tomesphere.com/paper/PMC13025878